Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $75.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors, primarily focusing on the potential of Structure Therapeutics’ lead asset, aleniglipron. As an oral, small molecule GLP-1 receptor agonist, aleniglipron is being developed for obesity and type 2 diabetes (T2D), and the upcoming Phase IIb data from the ACCESS and ACCESS-2 studies are expected to be significant catalysts for the company’s stock. Dolezal anticipates that the data could lead to a substantial increase in share value, potentially moving 100-200% upward, or a decrease of around 50%, depending on the outcomes.
Moreover, Dolezal highlights the competitive positioning of aleniglipron, which could become the second approved oral GLP-1 receptor agonist without a fasting requirement. This positions it favorably against competitors like Lilly’s orfoglipron, especially if aleniglipron’s therapeutic profile is comparable or superior. The analyst assigns a 50% probability of success for aleniglipron and estimates significant probability-adjusted peak sales in both obesity and T2D markets. These factors contribute to the optimistic outlook and the Buy rating for Structure Therapeutics.